BiotechTube

Mogamulizumab + Brentuximab vedotin

Phase 1Recruiting
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cutaneous T Cell Lymphoma

Conditions

Cutaneous T Cell Lymphoma, Mycosis Fungoides

Trial Timeline

May 1, 2023 → Jul 31, 2026

NCT ID
NCT05414500

About Mogamulizumab + Brentuximab vedotin

Mogamulizumab + Brentuximab vedotin is a phase 1 stage product being developed by Kyowa Kirin for Cutaneous T Cell Lymphoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05414500. Target conditions include Cutaneous T Cell Lymphoma, Mycosis Fungoides.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT05414500Phase 1Recruiting

Competing Products

20 competing products in Cutaneous T Cell Lymphoma

See all competitors
ProductCompanyStageHype Score
ONTAK (denileukin difitox, DAB389IL-2)EisaiApproved
85
ONTAKEisaiApproved
85
E7777 9 mcg/kgEisaiPhase 3
77
ONTAKEisaiApproved
85
MogamulizumabKyowa KirinApproved
85
MogamulizumabKyowa KirinPhase 2
52
KW-0761 + VorinostatKyowa KirinPhase 3
77
EnzastaurinEli LillyPhase 2
52
Clopidogrel + TicagrelorAstraZenecaApproved
85
PembrolizumabMerckPhase 2
52
Comparator: vorinostatMerckPre-clinical
23
PembrolizumabMerckPhase 2
52
TR701 FAMerckPhase 2
52
MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 MonthsMerckPhase 2
52
PembrolizumabMerckPhase 2
52
Tulisokibart + PlaceboMerckPhase 2
52
Aspirin + Ipilimumab + PembrolizumabMerckPhase 2
52
Pembrolizumab + MogamulizumabMerckPhase 2
52
TR-701 FA + LinezolidMerckPhase 3
77
Pimasertib + DacarbazineMerckPhase 2
52

Other Products from Kyowa Kirin

KRN23Approved
85
Istradefylline PillApproved
85
MogamulizumabApproved
85
KRN23Approved
85
KHK4827-Active + KHK4827-PlaceboApproved
85